Clinical Trials - January 14, 2025
Orexo announces positive topline data
Orexo has announced positive topline results from the clinical study OX640-002.
Clinical Trials - December 18, 2024
Hansa Biopharma announces positive full results
Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.
Clinical Trials - December 11, 2024
Immunovia announces positive outcome of clinical validation
Immunovia has announced the successful completion of the CLARITI study, (Clinical Validation of Next-Generation Test for Early-Stage Pancreatic Cancer) to detect early-stage pancreatic ductal adenocarcinoma (PDAC).
Clinical Trials - December 10, 2024
Modus Therapeutics initiates Phase II study
The first dose has been administered in the company’s Phase II clinical study evaluating the drug candidate sevuparin for the treatment of chronic kidney disease (CKD) with associated anemia.
Clinical Trials - December 3, 2024
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial
The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment.
Clinical Trials - November 19, 2024
Modus Therapeutics receives approval to initiate Phase IIa trial for Chronic Kidney Disease
Modus Therapeutics has received approval from the relevant authorities in Italy for its planned Phase IIa clinical trial with sevuparin.
